Hyperglycemia during Adjuvant Chemotherapy as a Prognostic Factor in Breast Cancer Patients without Diabetes

다국어 초록 (Multilingual Abstract)

Purpose: Breast cancer treatments, including chemotherapy, administered in combination with glucocorticoids can induce hyperglycemia. This study aimed to investigate the effect of hyperglycemia during adjuvant chemotherapy on the prognosis of breast cancer patients without a known history of diabetes.
Methods: In this study, 936 patients who underwent breast cancer surgery from 2010 to 2015 were initially selected as participants. Chemotherapy-related hyperglycemia was defined as fasting plasma glucose levels ≥ 100 mg/dL or random blood glucose levels ≥ 140 mg/dL during 2 or more cycles of adjuvant chemotherapy. After dividing the patients into the euglycemia and hyperglycemia groups, univariate and multivariate analyses were performed, and survival outcomes were analyzed by propensity score matching.
Results: The mean age of the patients was 47.4 ± 7.7 years, and the median follow-up period was 70.1 months. Eighty-two patients (19.4%) were diagnosed as having hyperglycemia.
There were significant differences between the euglycemia and hyperglycemia groups with respect to age, hypertension, body mass index, axillary surgery extents, nodal stage, and total steroid dosage. T stage, vascular invasion, and hyperglycemia were identified as prognostic factors of relapse-free survival (RFS). The 5-year RFS rates were 92.0% and 82.3% in the euglycemia and hyperglycemia groups, respectively, and there was a statistically significant difference between the 2 groups (p = 0.011). The 5-year overall survival rates were 94.6% and 92.0% in the euglycemia and hyperglycemia groups, respectively, showing no statistically significant difference between the 2 groups (p = 0.113).
Conclusion: These data suggest that hyperglycemia during adjuvant chemotherapy is a prognostic factor for RFS in breast cancer patients without diabetes.

참고문헌 (Reference)

1 Chen S, "The association between diabetes/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis" 96 : e7981-, 2017

2 Mohn A, "Persistence of impaired pancreatic β-cell function in children treated for acute lymphoblastic leukaemia" 363 : 127-128, 2004

3 Martin-Salces M, "Nutritional recommendations in hematopoietic stem cell transplantation" 24 : 769-775, 2008

4 Rosato V, "Metabolic syndrome and the risk of breast cancer in postmenopausal women" 22 : 2687-2692, 2011

5 Capasso I, "Metabolic syndrome affects breast cancer risk in postmenopausal women : National Cancer Institute of Naples experience" 10 : 1240-1243, 2010

6 Barone BB, "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and meta-analysis" 300 : 2754-2764, 2008

7 Accordino MK, "Incidence of hyperglycemia in non-diabetic patients with early-stage breast cancer treated with chemotherapy" 79 : 2019

8 Lipscombe LL, "Incidence of diabetes among postmenopausal breast cancer survivors" 56 : 476-483, 2013

9 Ali NA, "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality" 110 : 96-102, 2007

10 Sonabend RY, "Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia" 155 : 73-78, 2009

11 Brunello A, "Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity" 34 : 292-296, 2011

12 Zeng L, "Hyperglycaemia confers resistance to chemotherapy on breast cancer cells : the role of fatty acid synthase" 17 : 539-551, 2010

13 Li W, "Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer" 6 : 31119-31133, 2015

14 Kang X, "High glucose promotes tumor invasion and increases metastasis-associated protein expression in human lung epithelial cells by upregulating heme oxygenase-1 via reactive oxygen species or the TGF-β1/PI3K/Akt signaling pathway" 35 : 1008-1022, 2015

15 Hou Y, "High glucose levels promote the proliferation of breast cancer cells through GTPases" 9 : 429-436, 2017

16 Garufi A, "High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity" 33 : 79-, 2014

17 Tsai JR, "High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients" 35 : 461-471, 2012

18 Clore JN, "Glucocorticoid-induced hyperglycemia" 15 : 469-474, 2009

19 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" 68 : 394-424, 2018

20 Early Breast Cancer Trialists' Collaborative Group(EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials" 365 : 1687-1717, 2005

21 Lee YJ, "Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers" 5 : 371-376, 2004

22 American Diabetes Association, "Diagnosis and classification of diabetes mellitus" 31 (31): S55-S60, 2008

23 Zhao XB, "Diabetes mellitus and prognosis in women with breast cancer: a systematic review and meta-analysis" 95 : e5602-, 2016

24 Peairs KS, "Diabetes mellitus and breast cancer outcomes : a systematic review and meta-analysis" 29 : 40-46, 2011

25 Psarakis HM, "Clinical challenges in caring for patients with diabetes and cancer" 19 : 157-162, 2006

26 Yoo KE, "Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy" 23 : 1969-1977, 2015

27 황보율, "Acute Hyperglycemia Associated with Anti-Cancer Medication" 대한내분비학회 32 (32): 23-29, 2017